Novan Inc. thinks a deeper look at its first two Phase III trials for its molluscum contagiosum candidate SB206 shows a way toward filing for approval – assuming it receives confirmatory data from a third Phase III study – but the company may not have the financial runway to see its plans through.
Novan Still Hopeful But May Be Stranded After Phase III Molluscum Failure
Nitric oxide-releasing SB206 missed the primary endpoint in a pair of Phase III studies, but Novan hopes a third study and success on a secondary endpoint still can lead to filing for approval.